{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T05:10:50Z","timestamp":1696309850663},"reference-count":36,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2013,8,20]],"date-time":"2013-08-20T00:00:00Z","timestamp":1376956800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Influenza Resp Viruses"],"published-print":{"date-parts":[[2013,11]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The <jats:styled-content style=\"fixed-case\">W<\/jats:styled-content>orld <jats:styled-content style=\"fixed-case\">H<\/jats:styled-content>ealth <jats:styled-content style=\"fixed-case\">O<\/jats:styled-content>rganization recommends early antiviral treatment for patients with severe influenza illness or those at increased risk for severe illness.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>The aim of this study was to determine the proportion of cases with laboratory\u2010confirmed <jats:styled-content style=\"fixed-case\">A<\/jats:styled-content>(<jats:styled-content style=\"fixed-case\">H<\/jats:styled-content>1<jats:styled-content style=\"fixed-case\">N<\/jats:styled-content>1)pdm09 infection that have been treated with antivirals in Germany during the pandemic (<jats:styled-content style=\"fixed-case\">H<\/jats:styled-content>1<jats:styled-content style=\"fixed-case\">N<\/jats:styled-content>1) 2009 and to investigate factors associated with the use of antivirals.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We analyzed cases with laboratory\u2010confirmed <jats:styled-content style=\"fixed-case\">A<\/jats:styled-content>(<jats:styled-content style=\"fixed-case\">H<\/jats:styled-content>1<jats:styled-content style=\"fixed-case\">N<\/jats:styled-content>1)pdm09 infection notified to national health authorities in <jats:styled-content style=\"fixed-case\">G<\/jats:styled-content>ermany between week 29\/2009 and week 17\/2010 using multivariable logistic regression. Severity of disease was defined by pneumonia or death.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results and conclusions<\/jats:title><jats:p>Of 160\u00a0804 cases with laboratory\u2010confirmed <jats:styled-content style=\"fixed-case\">A<\/jats:styled-content>(<jats:styled-content style=\"fixed-case\">H<\/jats:styled-content>1<jats:styled-content style=\"fixed-case\">N<\/jats:styled-content>1)pdm09 infection, 22% were treated with antivirals. Cases with severe disease were more likely to be treated with antivirals than cases without severe disease (odds ratio\u00a0=\u00a01\u00b766; 95% confidence interval: 1\u00b746\u20131\u00b789). In the group with at least one underlying medical condition, only children aged between 1 and 4\u00a0years had significant lower odds for receiving antiviral treatment compared with cases in the age group 15 to 49\u00a0years (odds ratio\u00a0=\u00a00\u00b775; 95% confidence interval: 0\u00b76\u20130\u00b794). In conclusion, the implementation of international recommendations on use of antivirals differed according to the age of patients in Germany during the pandemic (<jats:styled-content style=\"fixed-case\">H<\/jats:styled-content>1<jats:styled-content style=\"fixed-case\">N<\/jats:styled-content>1) 2009. This indicates that the potential of antivirals to prevent severe influenza might not have been fully exhausted. The reasons leading to the observed differences in patient management need to be investigated.<\/jats:p><\/jats:sec>","DOI":"10.1111\/irv.12152","type":"journal-article","created":{"date-parts":[[2013,8,20]],"date-time":"2013-08-20T10:14:45Z","timestamp":1376993685000},"page":"1427-1432","source":"Crossref","is-referenced-by-count":3,"title":["Differential use of antivirals for treatment of patients with influenza A(<scp>H<\/scp>1<scp>N<\/scp>1)pdm09 in <scp>G<\/scp>ermany"],"prefix":"10.1111","volume":"7","author":[{"given":"Annicka","family":"Reuss","sequence":"first","affiliation":[{"name":"Department for Infectious Disease Epidemiology Robert Koch Institute Berlin Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Dehnert","sequence":"additional","affiliation":[{"name":"Department for Infectious Disease Epidemiology Robert Koch Institute Berlin Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silke","family":"Buda","sequence":"additional","affiliation":[{"name":"Department for Infectious Disease Epidemiology Robert Koch Institute Berlin Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter","family":"Haas","sequence":"additional","affiliation":[{"name":"Department for Infectious Disease Epidemiology Robert Koch Institute Berlin Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,8,20]]},"reference":[{"key":"e_1_2_5_2_1","unstructured":"World Health Organization.Guidelines for Pharmacological Management of Pandemic Influenza A(H1N1) 2009 and other Influenza Viruses. Available athttp:\/\/www.who.int\/csr\/resources\/publications\/swineflu\/h1n1_guidelines_pharmaceutical_mngt.pdf(Accessed 4 February 2013)."},{"key":"e_1_2_5_3_1","unstructured":"World Health Organization.Guidelines on the Use of Vaccines and Antivirals during Influenza Pandemics. Available athttp:\/\/whqlibdoc.who.int\/hq\/2004\/WHO_CDS_CSR_RMD_2004.8_eng.pdf(Accessed 4 February 2013)."},{"key":"e_1_2_5_4_1","unstructured":"Centers for Disease Control and Prevention.Updated interim recommendations for the use of antiviral medications in the treatment and prevention of influenza for the 2009\u201010 season. Available athttp:\/\/www.cdc.gov\/H1N1flu\/recommendations.htm(Accessed 8 June 2013)."},{"issue":"362","key":"e_1_2_5_5_1","first-page":"1708","article-title":"Clinical aspects of pandemic influenza A (H1N1) virus infection","volume":"2010","author":"Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza.","year":"2009","journal-title":"N Engl J Med"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00103-010-1158-0"},{"key":"e_1_2_5_7_1","unstructured":"World Health Organization.Comparable analysis of national pandemic influenza preparedness plans. Available athttp:\/\/www.who.int\/influenza\/resources\/documents\/comparative_analysis_php_2011_en.pdf(Accessed 4 February 2013)."},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.06.039834"},{"key":"e_1_2_5_9_1","unstructured":"World Health Organization.Pandemic influenza preparedness and response: a WHO guidance document. Available athttp:\/\/whqlibdoc.who.int\/publications\/2009\/9789241547680_eng.pdf(Accessed 4 February 2013)."},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis442"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0906695"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1496"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis636"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-011-0121-9"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-10-155"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid1702.101090"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid1811.120719"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq511"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir400"},{"key":"e_1_2_5_20_1","first-page":"CD002744","article-title":"Neuraminidase inhibitors for preventing and treating influenza in children (published trials only)","volume":"4","author":"Wang K","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-156-7-201204030-00411"},{"key":"e_1_2_5_22_1","unstructured":"Deutsche Gesellschaft f\u00fcr p\u00e4diatrische Infektiologie e. V. Aktualisierte Empfehlung der DGPI zur Diagnostik Therapie und Prophylaxe der Infektion mit dem Neuen Influenza A\/H1N1v\u2010Virus bei Kindern und Jugendlichen.Available athttp:\/\/dgpi.de\/go\/wp-content\/uploads\/2012\/12\/InflA-_H1N1v_DGPI-Empfehlungen_09Nov2009.pdf(Accessed 4 February 2013)."},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0029-1243862"},{"issue":"01","key":"e_1_2_5_24_1","first-page":"1","article-title":"Antiviral agents for the treatment and chemoprophylaxis of influenza \u2010 recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"60","author":"Fiore AE","year":"2011","journal-title":"MMWR Recomm Rep"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0029-1243910"},{"key":"e_1_2_5_26_1","unstructured":"European Medicines Agency (EMEA).CHMP Assessment Report on Novel Influenza (H1N1) outbreak Tamiflu (oseltamivir) Relenza (zanamivir) EMEA\/H\/A\u20105.3\/1172. Available athttp:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Other\/2009\/12\/WC500018448.pdf(Accessed 4 February 2013)."},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e3181cc4d01"},{"key":"e_1_2_5_28_1","unstructured":"U.S. Food and Drug Administration.Label for Tamiflu approved on 12\/21\/2012. Available athttp:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/021246s045lbl.pdf(Accessed 4 February 2013)."},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b5106"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61804-3"},{"key":"e_1_2_5_31_1","unstructured":"National Association of Statutory Health Insurance Physicians.Oseltamivir (Tamiflu); Zanamivir (Relenza). Available athttp:\/\/www.akdae.de\/Arzneimitteltherapie\/WA\/Archiv-Fertigarzneimittel\/Oseltamivir-Zanamivir.pdf(Accessed 4 February 2013)."},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1750-2659.2012.00384.x"},{"key":"e_1_2_5_33_1","first-page":"497","article-title":"Global monitoring of antiviral resistance in currently circulating human influenza viruses","volume":"86","author":"World Health Organization","year":"2011","journal-title":"Wkly Epidemiol Rec"},{"key":"e_1_2_5_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1750-2659.2012.00390.x"},{"key":"e_1_2_5_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03751.x"},{"key":"e_1_2_5_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-30726-3_22"},{"key":"e_1_2_5_37_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2807\/ese.15.49.19741-en","article-title":"Mortality of 2009 pandemic influenza A(H1N1) in Germany","volume":"15","author":"Wilking H","year":"2010","journal-title":"Euro Surveill"}],"container-title":["Influenza and Other Respiratory Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Firv.12152","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/irv.12152","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T07:42:07Z","timestamp":1696232527000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/irv.12152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,20]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["10.1111\/irv.12152"],"URL":"https:\/\/doi.org\/10.1111\/irv.12152","archive":["Portico"],"relation":{},"ISSN":["1750-2640","1750-2659"],"issn-type":[{"value":"1750-2640","type":"print"},{"value":"1750-2659","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,20]]}}}